Targeting SRC in glioblastoma tumors and brain metastases Rationale and preclinical studies

Glioblastoma (GBM) is an extremely aggressive infiltrative tumor with a poor prognosis The regulatory approval of bevacizumab for recurrent GBM has confirmed that molecularly targeted agents have potential for GBM treatment Preclinical data showing that SRC and SRC-family kinase (SFKs) mediate intracellular signaling pathways controlling key biologic/oncogenic processes provide a strong rationale for investigating SRC/SFK inhibitors e g dasatinib in GBM and clinical studies are underway The activity of these agents against solid tumors suggests that they may also be useful in treating brain metastases This article reviews the potential for using SRC/SFK inhibitors to treat GBM and brain metastases (C) 2010 Elsevier Ireland Ltd All rights reserved